EP1147204A1
(de)
*
|
1999-01-28 |
2001-10-24 |
Medical College Of Georgia Research Institute, Inc. |
Zusammensetzung und verfahren zur in vivo und in vitro abschwächung der genexpression mittels dobbelsträngigem rna
|
DE19956568A1
(de)
|
1999-01-30 |
2000-08-17 |
Roland Kreutzer |
Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
|
US8541548B2
(en)
*
|
1999-06-07 |
2013-09-24 |
Arrowhead Madison Inc. |
Compounds and methods for reversible modification of biologically active molecules
|
US20080281041A1
(en)
*
|
1999-06-07 |
2008-11-13 |
Rozema David B |
Reversibly Masked Polymers
|
GB9925459D0
(en)
*
|
1999-10-27 |
1999-12-29 |
Plant Bioscience Ltd |
Gene silencing
|
US7829693B2
(en)
*
|
1999-11-24 |
2010-11-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a target gene
|
DE10100586C1
(de)
*
|
2001-01-09 |
2002-04-11 |
Ribopharma Ag |
Verfahren zur Hemmung der Expression eines Ziegens
|
CA2774959C
(en)
|
2000-08-04 |
2016-05-31 |
Dmi Biosciences, Inc. |
Method of using diketopiperazines and composition containing them
|
US7767802B2
(en)
*
|
2001-01-09 |
2010-08-03 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of anti-apoptotic genes
|
US7423142B2
(en)
*
|
2001-01-09 |
2008-09-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of anti-apoptotic genes
|
US8546143B2
(en)
|
2001-01-09 |
2013-10-01 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a target gene
|
US20050153915A1
(en)
*
|
2001-05-18 |
2005-07-14 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of early growth response gene expression using short interfering nucleic acid (siNA)
|
US20050164966A1
(en)
*
|
2001-05-18 |
2005-07-28 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of type 1 insulin-like growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US7745418B2
(en)
|
2001-10-12 |
2010-06-29 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting viral replication
|
DE10163098B4
(de)
|
2001-10-12 |
2005-06-02 |
Alnylam Europe Ag |
Verfahren zur Hemmung der Replikation von Viren
|
DE10230997A1
(de)
*
|
2001-10-26 |
2003-07-17 |
Ribopharma Ag |
Medikament zur Erhöhung der Wirksamkeit eines Rezeptor-vermittelt Apoptose in Tumorzellen auslösenden Arzneimittels
|
US20040121348A1
(en)
*
|
2001-10-26 |
2004-06-24 |
Ribopharma Ag |
Compositions and methods for treating pancreatic cancer
|
US20040063654A1
(en)
*
|
2001-11-02 |
2004-04-01 |
Davis Mark E. |
Methods and compositions for therapeutic use of RNA interference
|
DE10202419A1
(de)
*
|
2002-01-22 |
2003-08-07 |
Ribopharma Ag |
Verfahren zur Hemmung der Expression eines durch eine Chromosomen-Aberration entstandenen Zielgens
|
US20050096289A1
(en)
*
|
2002-02-07 |
2005-05-05 |
Hans Prydz |
Methods and compositions for modulating tissue factor
|
AU2003223172A1
(en)
*
|
2002-02-12 |
2003-09-04 |
Quark Biotech, Inc. |
Use of the axl receptor for diagnosis and treatment of renal disease
|
EP1476492A1
(de)
*
|
2002-02-22 |
2004-11-17 |
Insert Therapeutics Inc. |
"kohlenhydratmodifizierte polymere, zusammensetzungen und verwendungszwecke in verbindung damit"
|
US8008355B2
(en)
*
|
2002-03-11 |
2011-08-30 |
Roche Madison Inc. |
Endosomolytic poly(vinyl ether) polymers
|
US8138383B2
(en)
*
|
2002-03-11 |
2012-03-20 |
Arrowhead Madison Inc. |
Membrane active heteropolymers
|
MXPA05002444A
(es)
|
2002-09-06 |
2005-09-30 |
Insert Therapeutics Inc |
Polimeros a base de ciclodextrina para el suministro de agentes terapeuticos.
|
US9719092B2
(en)
|
2002-11-14 |
2017-08-01 |
Thermo Fisher Scientific Inc. |
RNAi targeting CNTD2
|
WO2006006948A2
(en)
*
|
2002-11-14 |
2006-01-19 |
Dharmacon, Inc. |
METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
|
DK2284266T3
(da)
*
|
2002-11-14 |
2014-01-13 |
Thermo Fisher Scient Biosciences Inc |
sIRNA-MOLEKYLE MOD TP53
|
US7619081B2
(en)
*
|
2002-11-14 |
2009-11-17 |
Dharmacon, Inc. |
siRNA targeting coatomer protein complex, subunit beta 2 (COPB2)
|
US7691998B2
(en)
*
|
2002-11-14 |
2010-04-06 |
Dharmacon, Inc. |
siRNA targeting nucleoporin 62kDa (Nup62)
|
US7977471B2
(en)
*
|
2002-11-14 |
2011-07-12 |
Dharmacon, Inc. |
siRNA targeting TNFα
|
US7592442B2
(en)
*
|
2002-11-14 |
2009-09-22 |
Dharmacon, Inc. |
siRNA targeting ribonucleotide reductase M2 polypeptide (RRM2 or RNR-R2)
|
US7612196B2
(en)
*
|
2002-11-14 |
2009-11-03 |
Dharmacon, Inc. |
siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B)
|
US20100113307A1
(en)
*
|
2002-11-14 |
2010-05-06 |
Dharmacon, Inc. |
siRNA targeting vascular endothelial growth factor (VEGF)
|
US7635770B2
(en)
*
|
2002-11-14 |
2009-12-22 |
Dharmacon, Inc. |
siRNA targeting protein kinase N-3 (PKN-3)
|
US9839649B2
(en)
|
2002-11-14 |
2017-12-12 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
US20080268457A1
(en)
*
|
2002-11-14 |
2008-10-30 |
Dharmacon, Inc. |
siRNA targeting forkhead box P3 (FOXP3)
|
US7951935B2
(en)
|
2002-11-14 |
2011-05-31 |
Dharmacon, Inc. |
siRNA targeting v-myc myelocytomatosis viral oncogene homolog (MYC)
|
US9719094B2
(en)
|
2002-11-14 |
2017-08-01 |
Thermo Fisher Scientific Inc. |
RNAi targeting SEC61G
|
US9228186B2
(en)
|
2002-11-14 |
2016-01-05 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
US20090227780A1
(en)
*
|
2002-11-14 |
2009-09-10 |
Dharmacon, Inc. |
siRNA targeting connexin 43
|
US10011836B2
(en)
|
2002-11-14 |
2018-07-03 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
US9879266B2
(en)
|
2002-11-14 |
2018-01-30 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
US7781575B2
(en)
|
2002-11-14 |
2010-08-24 |
Dharmacon, Inc. |
siRNA targeting tumor protein 53 (p53)
|
US8198427B1
(en)
|
2002-11-14 |
2012-06-12 |
Dharmacon, Inc. |
SiRNA targeting catenin, beta-1 (CTNNB1)
|
US9771586B2
(en)
|
2002-11-14 |
2017-09-26 |
Thermo Fisher Scientific Inc. |
RNAi targeting ZNF205
|
CA2523467C
(en)
*
|
2003-05-15 |
2021-10-26 |
Dmi Biosciences, Inc. |
Treatment of t-cell mediated diseases
|
WO2005017109A2
(en)
*
|
2003-06-30 |
2005-02-24 |
Massachusetts Institute Of Technology |
Nucleic acids and polypeptides required for cell survival in the absence of rb
|
US20050136437A1
(en)
*
|
2003-08-25 |
2005-06-23 |
Nastech Pharmaceutical Company Inc. |
Nanoparticles for delivery of nucleic acids and stable double-stranded RNA
|
WO2005045032A2
(en)
*
|
2003-10-20 |
2005-05-19 |
Sima Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF EARLY GROWTH RESPONSE GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
WO2005051431A1
(en)
*
|
2003-11-25 |
2005-06-09 |
The University Of York |
Colloidal delivery system for biological therapeutic agents
|
WO2005062854A2
(en)
*
|
2003-12-19 |
2005-07-14 |
University Of Cincinnati |
Polyamides for nucleic acid delivery
|
MXPA06007269A
(es)
*
|
2003-12-23 |
2007-07-09 |
Univ Pennsylvania |
Composiciones y metodos para terapia combinada de enfermedad.
|
CA2558682A1
(en)
*
|
2004-02-20 |
2005-09-01 |
Genesis Research And Development Corporation Limited |
Targeted delivery of rna interference molecules for the treatment of ige-mediated disorders
|
EP1737956A2
(de)
*
|
2004-03-01 |
2007-01-03 |
Massachusetts Institute of Technology |
Therapeutika auf rnai-basis gegen allergische rhinitis und asthma
|
US20050202075A1
(en)
*
|
2004-03-12 |
2005-09-15 |
Pardridge William M. |
Delivery of genes encoding short hairpin RNA using receptor-specific nanocontainers
|
JP2005264046A
(ja)
*
|
2004-03-19 |
2005-09-29 |
Sony Corp |
刺激応答性ハイドロゲル、刺激応答性ハイドロゲルの製造方法、及び刺激応答性ハイドロゲルを用いた高分子アクチュエータ
|
CA2561741C
(en)
*
|
2004-04-05 |
2016-09-27 |
Alnylam Pharmaceuticals, Inc. |
Processes and reagents for oligonucleotide synthesis and purification
|
US20050260652A1
(en)
*
|
2004-04-15 |
2005-11-24 |
The General Hospital Corporation |
Compositions and methods that modulate RNA interference
|
US20110206639A1
(en)
*
|
2004-04-15 |
2011-08-25 |
Christie Vermeulen |
Replication competent viruses capable of silencing virus inhibitory factor expression
|
EP1586654A1
(de)
*
|
2004-04-15 |
2005-10-19 |
Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg |
Replikationskompetente Viren für Genabschaltung von Virusinaktivierungsfaktor
|
US7626014B2
(en)
|
2004-04-27 |
2009-12-01 |
Alnylam Pharmaceuticals |
Single-stranded and double-stranded oligonucleotides comprising a 2-arylpropyl moiety
|
EP1750776A2
(de)
*
|
2004-04-30 |
2007-02-14 |
Alnylam Pharmaceuticals Inc. |
Oligonukleotide mit c5-modifiziertem pyrimidin
|
US7605250B2
(en)
*
|
2004-05-12 |
2009-10-20 |
Dharmacon, Inc. |
siRNA targeting cAMP-specific phosphodiesterase 4D
|
AU2005247403A1
(en)
*
|
2004-05-17 |
2005-12-08 |
Combinatorx, Incorporated |
Methods and reagents for the treatment of immunoinflammatory disorders
|
US20050265927A1
(en)
*
|
2004-05-17 |
2005-12-01 |
Yale University |
Intranasal delivery of nucleic acid molecules
|
JP5435864B2
(ja)
|
2004-05-28 |
2014-03-05 |
アシュラジェン インコーポレイテッド |
マイクロrnaに関与する方法および組成物
|
US8815599B2
(en)
*
|
2004-06-01 |
2014-08-26 |
Pronai Therapeutics, Inc. |
Methods and compositions for the inhibition of gene expression
|
US20060040290A1
(en)
*
|
2004-06-23 |
2006-02-23 |
Applera Corporation |
Methods, compositions, and kits comprising PNA for RNA interference
|
JP2008504840A
(ja)
|
2004-06-30 |
2008-02-21 |
アルニラム ファーマスーティカルズ インコーポレイテッド |
非リン酸骨格結合を含むオリゴヌクレオチド
|
US8361976B2
(en)
*
|
2004-07-09 |
2013-01-29 |
University Of Massachusetts |
Therapeutic alteration of transplantable tissues through in situ or ex vivo exposure to RNA interference molecules
|
US7297786B2
(en)
*
|
2004-07-09 |
2007-11-20 |
University Of Iowa Research Foundation |
RNA interference in respiratory epitheial cells
|
US7579451B2
(en)
|
2004-07-21 |
2009-08-25 |
Alnylam Pharmaceuticals, Inc. |
Oligonucleotides comprising a modified or non-natural nucleobase
|
US20060030538A1
(en)
*
|
2004-07-21 |
2006-02-09 |
Medtronic, Inc. |
Methods for reducing or preventing localized fibrosis using SiRNA
|
US20060063208A1
(en)
*
|
2004-08-02 |
2006-03-23 |
Woolf Clifford J |
DRG11-responsive (DRAGON) gene and uses thereof
|
CA2574603C
(en)
|
2004-08-04 |
2014-11-04 |
Alnylam Pharmaceuticals, Inc. |
Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase
|
EP1799825B1
(de)
|
2004-10-05 |
2011-06-29 |
The California Institute of Technology |
Aptamer-regulierte nukleinsäuren und verwendungen davon
|
WO2006062581A2
(en)
*
|
2004-10-15 |
2006-06-15 |
Benitec, Inc. |
Delivery of therapeutic rnai agents for treating restenosis
|
EP1807514A1
(de)
*
|
2004-10-22 |
2007-07-18 |
Benitec, Inc. |
Therapeutische rnai für behandlung von psoriasis
|
DK2302055T3
(da)
|
2004-11-12 |
2014-10-13 |
Asuragen Inc |
Fremgangsmåder og sammensætninger involverende miRNA og miRNA-inhibitormolekyler
|
DE102005003788A1
(de)
*
|
2005-01-19 |
2006-07-20 |
Eberhard-Karls-Universität Tübingen Universitätsklinikum |
siRNA-Moleküle zur Behandlung von Blutgefäßen
|
WO2006078217A1
(en)
*
|
2005-01-24 |
2006-07-27 |
Avaris Ab |
COMPLEX CONTAINING SiRNA, ShRNA OR ANTISENSE MOLECULE AND FUNCTIONAL ENTITY, FOR IMPROVED SPECIFICITY AND DELIVERY
|
JPWO2006080118A1
(ja)
*
|
2005-01-28 |
2008-06-19 |
協和醗酵工業株式会社 |
標的遺伝子の発現を抑制する組成物
|
WO2006086681A2
(en)
*
|
2005-02-09 |
2006-08-17 |
Beth Israel Deaconess Medical Center, Inc. |
Methods of inhibiting smooth muscle cell migration and proliferation
|
CN101218256B
(zh)
|
2005-03-23 |
2017-04-19 |
根马布股份公司 |
用于治疗多发性骨髓瘤的cd38抗体
|
JP4131271B2
(ja)
*
|
2005-03-30 |
2008-08-13 |
ソニー株式会社 |
情報処理装置および方法、並びにプログラム
|
US20070033062A1
(en)
*
|
2005-04-28 |
2007-02-08 |
Oligoengine, Inc. |
Business methods, systems, and computer programs for designing customized biological assays and producing related catalogs and kits
|
JP2008201673A
(ja)
*
|
2005-05-16 |
2008-09-04 |
Kyushu Univ |
Rna含有組成物
|
US20090047319A1
(en)
*
|
2005-05-25 |
2009-02-19 |
Kenji Kadomatsu |
Pharmaceutical composition for obstructive vascular disease
|
EP1898936A4
(de)
*
|
2005-06-15 |
2009-05-06 |
London Health Sci Ct Res Inc |
Verfahren zur krebsbehandlung mit sirna-silencing
|
EP1934348B1
(de)
*
|
2005-10-11 |
2018-05-02 |
Ben-Gurion University Of The Negev Research And Development Authority |
Zusammensetzung zum silencing der expression von vdac1 und verwendungen davon
|
TW200800235A
(en)
|
2005-10-18 |
2008-01-01 |
Otsuka Pharma Co Ltd |
Carrier composition for nucleic acid transport
|
WO2007051303A1
(en)
|
2005-11-02 |
2007-05-10 |
Protiva Biotherapeutics, Inc. |
MODIFIED siRNA MOLECULES AND USES THEREOF
|
ES2419106T3
(es)
*
|
2005-12-01 |
2013-08-19 |
Pronai Therapeutics, Inc. |
Formulación de liposomas anfóteros
|
WO2007067733A2
(en)
*
|
2005-12-09 |
2007-06-14 |
Massachusetts Institute Of Technology |
Compositions and methods to monitor rna delivery to cells
|
EP1968643A2
(de)
*
|
2005-12-16 |
2008-09-17 |
Diatos |
Zell-penetrierende peptid-konjugate zur abgabe von nukleinsäuren in eine zelle
|
US20070172430A1
(en)
*
|
2006-01-20 |
2007-07-26 |
Nastech Pharmaceutical Company Inc. |
Dry powder compositions for rna influenza therapeutics
|
US8323967B2
(en)
*
|
2006-04-05 |
2012-12-04 |
Joslin Diabetes Center, Inc. |
Enhancing stem cell mobilization
|
US20070276134A1
(en)
*
|
2006-05-24 |
2007-11-29 |
Nastech Pharmaceutical Company Inc. |
Compositions and methods for complexes of nucleic acids and organic cations
|
US8501478B2
(en)
*
|
2006-06-15 |
2013-08-06 |
University Of Cincinnati |
Trehalose click polymers for delivery of biologically active molecules
|
CN102614528B
(zh)
*
|
2006-08-18 |
2014-02-26 |
箭头研究公司 |
用于体内递送多核苷酸的多缀合物
|
US8017109B2
(en)
*
|
2006-08-18 |
2011-09-13 |
Roche Madison Inc. |
Endosomolytic poly(acrylate) polymers
|
WO2008036741A2
(en)
*
|
2006-09-19 |
2008-03-27 |
Asuragen, Inc. |
Mir-200 regulated genes and pathways as targets for therapeutic intervention
|
WO2008058291A2
(en)
|
2006-11-09 |
2008-05-15 |
California Institute Of Technology |
Modular aptamer-regulated ribozymes
|
CA2671850A1
(en)
*
|
2006-12-08 |
2008-06-19 |
Massachusetts Institute Of Technology |
Delivery of nanoparticles and/or agents to cells
|
US20080176958A1
(en)
|
2007-01-24 |
2008-07-24 |
Insert Therapeutics, Inc. |
Cyclodextrin-based polymers for therapeutics delivery
|
EP2139908A4
(de)
|
2007-03-12 |
2011-02-16 |
Antigen Express Inc |
Li-suppression unter beteiligung von li-rnai in der krebs-immuntherapie
|
US8133553B2
(en)
|
2007-06-18 |
2012-03-13 |
Zimmer, Inc. |
Process for forming a ceramic layer
|
US8309521B2
(en)
|
2007-06-19 |
2012-11-13 |
Zimmer, Inc. |
Spacer with a coating thereon for use with an implant device
|
GB0711952D0
(en)
*
|
2007-06-20 |
2007-08-01 |
King S College London |
Microspheres
|
US20090082217A1
(en)
*
|
2007-07-16 |
2009-03-26 |
California Institute Of Technology |
Selection of nucleic acid-based sensor domains within nucleic acid switch platform
|
US8367815B2
(en)
*
|
2007-08-28 |
2013-02-05 |
California Institute Of Technology |
Modular polynucleotides for ligand-controlled regulatory systems
|
US20120165387A1
(en)
|
2007-08-28 |
2012-06-28 |
Smolke Christina D |
General composition framework for ligand-controlled RNA regulatory systems
|
US8865667B2
(en)
|
2007-09-12 |
2014-10-21 |
California Institute Of Technology |
Higher-order cellular information processing devices
|
EP2198050A1
(de)
|
2007-09-14 |
2010-06-23 |
Asuragen, INC. |
Mikrornas mit unterschiedlicher expression bei zervikalkarzinom und verwendungen davon
|
US8608049B2
(en)
|
2007-10-10 |
2013-12-17 |
Zimmer, Inc. |
Method for bonding a tantalum structure to a cobalt-alloy substrate
|
UA97559C2
(uk)
*
|
2007-11-08 |
2012-02-27 |
Оцука Фармасьютікал Ко., Лтд. |
Комплекс нуклеїнової кислоти і композиція для доставки нуклеїнової кислоти
|
US8071562B2
(en)
|
2007-12-01 |
2011-12-06 |
Mirna Therapeutics, Inc. |
MiR-124 regulated genes and pathways as targets for therapeutic intervention
|
US9029524B2
(en)
*
|
2007-12-10 |
2015-05-12 |
California Institute Of Technology |
Signal activated RNA interference
|
FR2925491B1
(fr)
*
|
2007-12-19 |
2010-09-03 |
Oz Biosciences Sas |
Nouvelle classe de lipides cationiques pour le transport d'agents actifs dans les cellules
|
CA2710713C
(en)
|
2007-12-27 |
2017-09-19 |
Protiva Biotherapeutics, Inc. |
Silencing of polo-like kinase expression using interfering rna
|
WO2009102427A2
(en)
|
2008-02-11 |
2009-08-20 |
Rxi Pharmaceuticals Corp. |
Modified rnai polynucleotides and uses thereof
|
FR2928373B1
(fr)
|
2008-03-05 |
2010-12-31 |
Centre Nat Rech Scient |
Polymere derive de la polyethylenimine lineaire pour le transfert de gene.
|
US20090226531A1
(en)
*
|
2008-03-07 |
2009-09-10 |
Allergan, Inc. |
Methods and composition for intraocular delivery of therapeutic sirna
|
AU2009236219B8
(en)
|
2008-04-15 |
2015-06-25 |
Arbutus Biopharma Corporation |
Silencing of CSN5 gene expression using interfering RNA
|
EP2285960B1
(de)
|
2008-05-08 |
2015-07-08 |
Asuragen, INC. |
Zusammensetzungen und verfahren in zusammenhang mit der mirna-184modulation von neovaskularisation oder angiogenese
|
WO2009146320A1
(en)
|
2008-05-27 |
2009-12-03 |
Dmi Life Sciences, Inc. |
Therapeutic methods and compounds
|
WO2010008582A2
(en)
|
2008-07-18 |
2010-01-21 |
Rxi Pharmaceuticals Corporation |
Phagocytic cell drug delivery system
|
EP2949752B1
(de)
|
2008-09-22 |
2017-12-20 |
RXi Pharmaceuticals Corporation |
Selbstfreisetzende rnai-verbindungen von reduzierter grösse
|
AU2009308380B2
(en)
*
|
2008-10-22 |
2015-05-28 |
Suzhou Ribo Life Science Co., Ltd. |
Methods for treating eye disorders
|
WO2010059226A2
(en)
|
2008-11-19 |
2010-05-27 |
Rxi Pharmaceuticals Corporation |
Inhibition of map4k4 through rnai
|
WO2010078536A1
(en)
|
2009-01-05 |
2010-07-08 |
Rxi Pharmaceuticals Corporation |
Inhibition of pcsk9 through rnai
|
US9745574B2
(en)
|
2009-02-04 |
2017-08-29 |
Rxi Pharmaceuticals Corporation |
RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
|
US8329882B2
(en)
|
2009-02-18 |
2012-12-11 |
California Institute Of Technology |
Genetic control of mammalian cells with synthetic RNA regulatory systems
|
WO2010101226A1
(ja)
*
|
2009-03-04 |
2010-09-10 |
大塚製薬株式会社 |
核酸複合体、及び核酸送達用組成物
|
US9145555B2
(en)
|
2009-04-02 |
2015-09-29 |
California Institute Of Technology |
Integrated—ligand-responsive microRNAs
|
WO2011006011A2
(en)
*
|
2009-07-08 |
2011-01-13 |
Virginia Tech Intellectual Properties Inc. |
Theranostic polycation beacons comprising oligoethyleneamine repeating units and lanthanide chelates
|
CN101624596B
(zh)
*
|
2009-08-12 |
2011-01-26 |
广州金琪基因技术研究发展中心 |
一种靶向c-myc癌基因的外指引序列
|
US9468650B2
(en)
|
2009-09-16 |
2016-10-18 |
Duke University |
Inhibition of endosomal toll-like receptor activation
|
US9799416B2
(en)
*
|
2009-11-06 |
2017-10-24 |
Terrapower, Llc |
Methods and systems for migrating fuel assemblies in a nuclear fission reactor
|
DK2539451T3
(da)
*
|
2010-02-24 |
2016-04-04 |
Arrowhead Res Corp |
Sammensætninger til målrettet tilførsel af siRNA
|
CN110042099A
(zh)
|
2010-03-24 |
2019-07-23 |
菲奥医药公司 |
皮肤与纤维化症候中的rna干扰
|
RU2615143C2
(ru)
|
2010-03-24 |
2017-04-04 |
Адвирна |
Самодоставляющие PHKi соединения уменьшенного размера
|
CN106074591B
(zh)
|
2010-03-24 |
2020-01-14 |
菲奥医药公司 |
眼部症候中的rna干扰
|
US20130164380A1
(en)
|
2010-06-17 |
2013-06-27 |
Actogenix Nv |
Compositions and methods for treating inflammatory conditions
|
WO2012033792A2
(en)
|
2010-09-07 |
2012-03-15 |
Dmi Acquisition Corp. |
Treatment of diseases
|
EP2718269B1
(de)
|
2011-06-08 |
2018-01-31 |
Translate Bio, Inc. |
Spaltbare lipide
|
WO2013040251A2
(en)
|
2011-09-13 |
2013-03-21 |
Asurgen, Inc. |
Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease
|
AU2012323305B2
(en)
|
2011-10-10 |
2017-07-27 |
Ampio Pharmaceuticals, Inc. |
Treatment of degenerative joint disease
|
MY172699A
(en)
|
2011-10-10 |
2019-12-10 |
Ampio Pharmaceuticals Inc |
Implantable medical devices with increased immune tolerance, and methods for making and implanting
|
AU2012328605B9
(en)
|
2011-10-28 |
2017-08-03 |
Ampio Pharmaceuticals, Inc. |
Treatment of rhinitis
|
WO2013075132A1
(en)
|
2011-11-17 |
2013-05-23 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Therapeutic rna switches compositions and methods of use
|
US9035039B2
(en)
|
2011-12-22 |
2015-05-19 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing SMAD4
|
CN104053776A
(zh)
*
|
2012-01-04 |
2014-09-17 |
夸克制药公司 |
Casp2的双链rna化合物及其用途
|
US20160015808A1
(en)
|
2012-02-21 |
2016-01-21 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Tam receptors as virus entry cofactors
|
MX2014010016A
(es)
|
2012-02-21 |
2015-06-05 |
Inst Nat Sante Rech Med |
Receptores de mucina de inmunoglobulina de celula t (tim) como co-factores de entrada del virus.
|
EA037448B1
(ru)
*
|
2012-06-08 |
2021-03-30 |
Этрис Гмбх |
Способ доставки в легкие терапевтической мрнк с pei и фармацевтическая композиция
|
JP2015524418A
(ja)
|
2012-07-27 |
2015-08-24 |
アンスティテュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
血管内皮細胞への髄膜炎菌の線毛媒介接着の受容体としてのcd147
|
US20140094432A1
(en)
|
2012-10-02 |
2014-04-03 |
Cerulean Pharma Inc. |
Methods and systems for polymer precipitation and generation of particles
|
KR102170266B1
(ko)
*
|
2013-02-27 |
2020-10-27 |
한국과학기술원 |
다당류 고분자-siRNA 그라프트 접합체, 이를 포함하는 siRNA 전달체 및 이의 제조방법
|
WO2014160211A1
(en)
*
|
2013-03-13 |
2014-10-02 |
Isis Pharmaceuticals, Inc. |
Modulation of inflammatory responses by c-reactive protein
|
US9808454B2
(en)
|
2013-03-15 |
2017-11-07 |
Ampio Pharmaceuticals, Inc. |
Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same
|
CN106061488B
(zh)
|
2013-12-02 |
2021-04-09 |
菲奥医药公司 |
癌症的免疫治疗
|
CA2932753A1
(en)
|
2013-12-04 |
2015-06-11 |
Rxi Pharmaceuticals Corporation |
Methods for treatment of wound healing utilizing chemically modified oligonucleotides
|
US9752145B2
(en)
|
2014-03-17 |
2017-09-05 |
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College |
Compositions and methods for reducing C/EBP homologous protein activity in myeloid-derived suppressor cells
|
US11279934B2
(en)
|
2014-04-28 |
2022-03-22 |
Phio Pharmaceuticals Corp. |
Methods for treating cancer using nucleic acids targeting MDM2 or MYCN
|
WO2015168605A1
(en)
|
2014-05-01 |
2015-11-05 |
Rxi Pharmaceuticals Corporation |
Methods for treatment of disorders in the front of the eye utilizing nucleic acid molecules
|
US9956217B2
(en)
|
2014-08-18 |
2018-05-01 |
Ampio Pharmaceuticals, Inc. |
Treatment of joint conditions
|
US10900039B2
(en)
|
2014-09-05 |
2021-01-26 |
Phio Pharmaceuticals Corp. |
Methods for treating aging and skin disorders using nucleic acids targeting Tyr or MMP1
|
SG11201702662UA
(en)
|
2014-10-02 |
2017-04-27 |
Protiva Biotherapeutics Inc |
Compositions and methods for silencing hepatitis b virus gene expression
|
WO2016197132A1
(en)
|
2015-06-04 |
2016-12-08 |
Protiva Biotherapeutics Inc. |
Treating hepatitis b virus infection using crispr
|
WO2016209969A1
(en)
|
2015-06-22 |
2016-12-29 |
Ampio Pharmaceuticals, Inc. |
Use of low molecular weight fractions of human serum albumin in treating diseases
|
WO2017007825A1
(en)
|
2015-07-06 |
2017-01-12 |
Rxi Pharmaceuticals Corporation |
Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
|
EP3862005A1
(de)
|
2015-07-06 |
2021-08-11 |
Phio Pharmaceuticals Corp. |
Gegen superoxid-dismutase 1 (sod1) gerichtete nukleinsäuremoleküle
|
WO2017019891A2
(en)
|
2015-07-29 |
2017-02-02 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing hepatitis b virus gene expression
|
EP3365446A4
(de)
|
2015-10-19 |
2019-06-26 |
Phio Pharmaceuticals Corp. |
Gegen lange nichtcodierende rna gerichtete kleine selbstfreisetzende nukleinsäureverbindungen
|
US20200123499A1
(en)
|
2015-12-02 |
2020-04-23 |
Massachusetts Institute Of Technology |
Method for efficient generation of neurons from non-neuronal cells
|
CA3066361A1
(en)
|
2017-06-07 |
2018-12-13 |
Shifamed Holdings, Llc |
Intravascular fluid movement devices, systems, and methods of use
|
US11511103B2
(en)
|
2017-11-13 |
2022-11-29 |
Shifamed Holdings, Llc |
Intravascular fluid movement devices, systems, and methods of use
|
US20200352913A1
(en)
|
2017-11-23 |
2020-11-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method for treating dengue virus infection
|
CN112004563B
(zh)
|
2018-02-01 |
2024-08-06 |
施菲姆德控股有限责任公司 |
血管内血泵以及使用和制造方法
|
WO2021011473A1
(en)
|
2019-07-12 |
2021-01-21 |
Shifamed Holdings, Llc |
Intravascular blood pumps and methods of manufacture and use
|
WO2021016372A1
(en)
|
2019-07-22 |
2021-01-28 |
Shifamed Holdings, Llc |
Intravascular blood pumps with struts and methods of use and manufacture
|
US11724089B2
(en)
|
2019-09-25 |
2023-08-15 |
Shifamed Holdings, Llc |
Intravascular blood pump systems and methods of use and control thereof
|
CN115135765A
(zh)
|
2019-11-08 |
2022-09-30 |
菲奥医药公司 |
用于免疫治疗的靶向含布罗莫结构域之蛋白4(brd4)的经化学修饰的寡核苷酸
|
EP4085136A1
(de)
|
2019-12-31 |
2022-11-09 |
Phio Pharmaceuticals Corp. |
Chemisch modifizierte oligonukleotide mit verbesserter systemischer abgabe
|
WO2021236852A1
(en)
|
2020-05-20 |
2021-11-25 |
Sana Biotechnology, Inc. |
Methods and compositions for treatment of viral infections
|
EP4204447A1
(de)
|
2020-08-28 |
2023-07-05 |
Sana Biotechnology, Inc. |
Modifizierte antivirale bindemittel
|
WO2023015264A1
(en)
|
2021-08-04 |
2023-02-09 |
Phio Pharmaceuticals Corp. |
Immunotherapy of cancer utilizing natural killer cells treated with chemically modified oligonucleotides
|
JP2024529025A
(ja)
|
2021-08-04 |
2024-08-01 |
フィオ ファーマシューティカルズ コーポレーション |
化学修飾されたオリゴヌクレオチド
|